This product is a derivative of rifamycin and is the first non-aminoglycoside intestinal antibiotic. This product has a strong effect and a broad antibacterial spectrum. It has good antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus faecalis among Gram-positive aerobic bacteria, and Salmonella, Escherichia coli, Shigella and Yersinia enterocolitica among Gram-negative aerobic bacteria. This product has high antibacterial activity against Proteus, Clostridium difficile among Gram-positive anaerobic bacteria, and Bacteroides among Gram-negative anaerobic bacteria. When using this product, there is no need to use intestinal antispasmodics (such as lopramamide, etc.) or intestinal adsorbents (such as white clay, pectin, etc.). This product acts quickly, and diarrhea will no longer occur after 2 days, and abdominal cramps, headaches, nausea, and vomiting symptoms will disappear quickly. This product is not absorbed and maintains extremely high concentrations in the intestine, but does not exist in other organs. Features superior to neomycin, streptomycin and other aminoglycoside antibiotics: ① This product does not damage hearing function; ② It does not cause renal damage; ③ Parasitic normal flora, especially non-pathogenic enteric bacteria Escherichia coli, quickly relocate to the intestines to avoid repeated infection; ④ Intestinal mucosal inflammation may tend to disappear. Mucosal inflammation is a contraindication to the use of topical aminoglycosides, because the inflammation may be aggravated after medication.

This product is a 4-azasteroid compound that is a specific inhibitor of the intracellular enzyme type II 5-reductase in the process of testosterone metabolism into the more potent androgen dihydrotestosterone (DHT). This product is very effective in reducing DHT in the blood and prostate. Finasteride has no affinity for androgen receptors.

This product belongs to the class of thiazolidinediones oral antidiabetic drugs, and is a highly selective peroxisome proliferator-activated receptor γ (PPARγ) agonist, which controls blood sugar levels by increasing peripheral and liver insulin sensitivity. Its main mechanism of action is to activate PPARγ nuclear receptors in tissues such as fat, skeletal muscle and liver where insulin acts, thereby regulating the transcription of insulin-responsive genes and controlling the production, transport and utilization of blood sugar.

It inhibits the voltage-dependent transmembrane calcium ion flow of smooth muscle, has a highly selective effect on vascular smooth muscle, dilates peripheral blood vessels and coronary blood vessels, improves oxygen supply due to coronary artery dilation, reduces afterload and reduces oxygen consumption. The therapeutic dose has no negative myocardial effect and does not affect the excitement and conduction of the heart, and has a certain effect of natriuresis. Long-term treatment does not produce tolerance.

This product is a quinolone antibacterial drug. It is a broad-spectrum antibacterial drug. It has obvious antibacterial effects on Gram-positive bacteria including Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, and Enterococcus faecalis; it also has good antibacterial effects on Gram-negative bacteria Escherichia coli, Klebsiella, Salmonella, Shigella, Vibrio parahaemolyticus, Proteus, Enterobacter, Pseudomonas, Acinetobacter, Neisseria (Neisseria gonorrhoeae, etc.). This product also has good antibacterial effects on mycoplasma, chlamydia, Legionella, anaerobic bacteria including Bacteroides fragilis and Mycobacterium. The mechanism of action of this product is to inhibit the action of DNA gyrase in the process of bacterial DNA synthesis and play a bactericidal role.